Tocilizumab (ClinicalTrials.gov Identifier: NCT0246996
 Tocilizumab is a monoclonal antibody which is a competitive inhibitor of  interleukin-6 (IL-6), preventing IL-6 from binding to its receptor (IL-6R). This prevents the pro-inflammatory IL-6 from signaling to mediators which trigger inflammation through B and T cells \cite{Khalid2017}.  In A Trial of Tocilizumab in ALS Subjects (TCZALS-001) tocilizumab, also known as Actemr, was tested for efficacy in ALS patients from 18-75 of both genders. Patients that were receiving a stable dose of riluzole and those not taking riluzole, and women of child-bearing age were eligible. Efficacy was determined by the mean change in ALSFRS-R total score, Rate of Decline in Slow Vital Capacity (SVC),  Number of Patients Tolerant to Study Drug and the primary outcome measure was  Rates of All-cause Mortality .  Patients (n=16, treatment group, n=8 placebo) received 8mg/kg of IV tocilizumab every 4 weeks for 3 months via IV infusion.